Key Points
- Urogen Pharma insider Mark Schoenberg sold 871 shares at an average price of $42.92, totaling $37,383.32. He retained 59,882 shares valued at approximately $2.57 million.
- Schoenberg has made several additional sales this year, including a $2.85 million transaction in August and two $400,000-plus sales in June and July.
- Urogen shares opened at $45, with analysts maintaining a “Moderate Buy” consensus and an average price target of $52.38; institutional investors own 91.29% of the stock.
Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 871 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the sale, the insider directly owned 59,882 shares in the company, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Mark Schoenberg also recently made the following trade(s):
- On Thursday, August 20th, Mark Schoenberg sold 60,677 shares of Urogen Pharma stock. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85.
- On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total value of $400,000.00.
- On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00.
Urogen Pharma Trading Up 2.7%
NASDAQ:URGN opened at $45.00 on Thursday. The company's 50-day moving average price is $43.16 and its 200-day moving average price is $31.31. The company has a market cap of $2.20 billion, a P/E ratio of -22.73 and a beta of 1.57. Urogen Pharma has a twelve month low of $15.86 and a twelve month high of $50.81.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analysts' expectations of $63.55 million. On average, analysts expect that Urogen Pharma will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Urogen Pharma
Institutional investors and hedge funds have recently made changes to their positions in the stock. Opaleye Management Inc. boosted its position in shares of Urogen Pharma by 0.7% during the 2nd quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company's stock worth $52,992,000 after purchasing an additional 9,996 shares during the period. Engineers Gate Manager LP purchased a new stake in Urogen Pharma in the second quarter valued at approximately $603,000. Squarepoint Ops LLC purchased a new stake in Urogen Pharma in the second quarter valued at approximately $431,000. California State Teachers Retirement System lifted its stake in Urogen Pharma by 4,168.7% during the second quarter. California State Teachers Retirement System now owns 1,654,123 shares of the company's stock worth $60,872,000 after purchasing an additional 1,615,373 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Urogen Pharma by 15.1% during the second quarter. Wellington Management Group LLP now owns 115,362 shares of the company's stock worth $4,245,000 after purchasing an additional 15,147 shares in the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Guggenheim lifted their price objective on Urogen Pharma from $42.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Oppenheimer upped their target price on Urogen Pharma from $40.00 to $50.00 and gave the company an "outperform" rating in a report on Thursday, July 16th. HC Wainwright raised their target price on Urogen Pharma from $45.00 to $75.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. TD Cowen lifted their price target on Urogen Pharma from $50.00 to $60.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Finally, UBS Group reissued a "buy" rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Urogen Pharma presently has a consensus rating of "Moderate Buy" and an average price target of $52.38.
View Our Latest Report on URGN
Urogen Pharma Company Profile
(
Get Free Report)
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
